Id
|
Protein
|
PTM type
|
Site
|
Species
|
Disease
|
Celline
|
Drug
|
Regulatory
|
Score
|
Ref.
|
acc1301 |
ERK2 |
phosphorylation |
Thr185 |
human |
Thyroid Cancer |
TPC-1 |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1302 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Thyroid Cancer |
TPC-1 |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1303 |
ERK1 |
phosphorylation |
Thr202 |
human |
Melanoma |
LOXIMVI |
TRAIL |
Enhancing |
5.0 |
25867065
|
acc1304 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Melanoma |
LOXIMVI |
TRAIL |
Enhancing |
5.0 |
25867065
|
acc1305 |
ERK2 |
phosphorylation |
Thr185 |
human |
Melanoma |
LOXIMVI |
TRAIL |
Enhancing |
5.0 |
25867065
|
acc1306 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Melanoma |
LOXIMVI |
TRAIL |
Enhancing |
5.0 |
25867065
|
acc1307 |
ERK1 |
phosphorylation |
Thr202 |
human |
Melanoma |
A375 |
TRAIL |
Enhancing |
5.0 |
25867065
|
acc1308 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Melanoma |
A375 |
TRAIL |
Enhancing |
5.0 |
25867065
|
acc1309 |
ERK2 |
phosphorylation |
Thr185 |
human |
Melanoma |
A375 |
TRAIL |
Enhancing |
5.0 |
25867065
|
acc1310 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Melanoma |
A375 |
TRAIL |
Enhancing |
5.0 |
25867065
|
acc1311 |
ERK2 |
phosphorylation |
Thr185 |
human |
Thyroid Cancer |
LOXIMVI |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1312 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Thyroid Cancer |
LOXIMVI |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1313 |
ERK1 |
phosphorylation |
Thr202 |
human |
Thyroid Cancer |
BCPAP |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1314 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Thyroid Cancer |
BCPAP |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1315 |
ERK2 |
phosphorylation |
Thr185 |
human |
Thyroid Cancer |
BCPAP |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1316 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Thyroid Cancer |
BCPAP |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1317 |
ERK1 |
phosphorylation |
Thr202 |
human |
Thyroid Cancer |
TPC-1 |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1318 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Thyroid Cancer |
TPC-1 |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1319 |
Chk1 |
phosphorylation |
Ser280 |
human |
Melanoma |
A375(PLX4032-res) |
PLX4032 + PF477736 |
Associated |
4.0 |
30100999
|
acc1320 |
Chk1 |
phosphorylation |
Ser280 |
human |
Melanoma |
WM9(PLX4032-res) |
PLX4032 + PF477736 |
Associated |
4.0 |
30100999
|
acc1321 |
Chk1 |
phosphorylation |
Ser296 |
human |
Melanoma |
A375(PLX4032-res) |
PLX4032 + PF477736 |
Associated |
4.0 |
30100999
|
acc1322 |
Chk1 |
phosphorylation |
Ser296 |
human |
Melanoma |
WM9(PLX4032-res) |
PLX4032 + PF477736 |
Associated |
4.0 |
30100999
|
acc1323 |
Chk1 |
phosphorylation |
Ser317 |
human |
Melanoma |
A375(PLX4032-res) |
PLX4032 + PF477736 |
Associated |
4.0 |
30100999
|
acc1324 |
Chk1 |
phosphorylation |
Ser317 |
human |
Melanoma |
WM9(PLX4032-res) |
PLX4032 + PF477736 |
Associated |
4.0 |
30100999
|
acc1325 |
Chk1 |
phosphorylation |
Ser345 |
human |
Melanoma |
A375(PLX4032-res) |
PLX4032 + PF477736 |
Associated |
4.0 |
30100999
|
acc1326 |
Chk1 |
phosphorylation |
Ser345 |
human |
Melanoma |
WM9(PLX4032-res) |
PLX4032 + PF477736 |
Associated |
4.0 |
30100999
|
acc1327 |
ERK1 |
phosphorylation |
Thr202 |
human |
Melanoma |
SB01 |
Bafetinib + Trametinib |
Associated |
4.0 |
29717260
|
acc1328 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Melanoma |
SB01 |
Bafetinib + Trametinib |
Associated |
4.0 |
29717260
|
acc1329 |
ERK2 |
phosphorylation |
Thr185 |
human |
Melanoma |
SB01 |
Bafetinib + Trametinib |
Associated |
4.0 |
29717260
|
acc1330 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Melanoma |
SB01 |
Bafetinib + Trametinib |
Associated |
4.0 |
29717260
|
acc1331 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
MDA-MB-231 |
Rapamycin |
Associated |
4.0 |
22422409
|
acc1332 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
MDA-MB-435 |
Rapamycin |
Associated |
4.0 |
22422409
|
acc1333 |
AKT |
phosphorylation |
Thr308 |
human |
Breast Cancer |
MDA-MB-231 |
Rapamycin |
Associated |
4.0 |
22422409
|
acc1334 |
AKT |
phosphorylation |
Thr308 |
human |
Breast Cancer |
MDA-MB-435 |
Rapamycin |
Associated |
4.0 |
22422409
|
acc1335 |
AKT |
phosphorylation |
Ser473 |
human |
Osteosarcoma |
OS2 |
Rapamycin |
Impairing |
5.0 |
20486173
|
acc1336 |
AKT |
phosphorylation |
Ser473 |
human |
Osteosarcoma |
OS9 |
Rapamycin |
Impairing |
5.0 |
20486173
|
acc1337 |
AKT |
phosphorylation |
Ser473 |
human |
Osteosarcoma |
OS17 |
Rapamycin |
Impairing |
5.0 |
20486173
|
acc1338 |
eIF4E |
phosphorylation |
Ser209 |
human |
Prostate Cancer |
DU145 |
MNK-inh |
Associated |
4.0 |
18809972
|
acc1339 |
eIF4E |
phosphorylation |
Ser209 |
human |
Prostate Cancer |
PC3 |
Rapamycin |
Associated |
4.0 |
18809972
|
acc1340 |
eIF4E |
phosphorylation |
Ser209 |
human |
Prostate Cancer |
LNCaP |
Rapamycin |
Associated |
4.0 |
18809972
|
acc1341 |
mTOR |
phosphorylation |
Ser2448 |
human |
Breast Cancer |
MCF7 |
Rapamycin |
Associated |
3.0 |
30154572
|
acc1342 |
claudin-7 |
phosphorylation |
Ser204 |
human |
Lung Cancer |
H522 |
Cisplatin |
Enhancing |
5.0 |
23433123
|
acc1343 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
MDA-MB-468 |
IBP OE |
Associated |
3.0 |
24113176
|
acc1344 |
mTOR |
phosphorylation |
Ser2481 |
human |
Breast Cancer |
MDA-MB-468 |
IBP OE |
Associated |
3.0 |
24113176
|
acc1345 |
FOXO3a |
phosphorylation |
Thr32 |
human |
Breast Cancer |
MDA-MB-468 |
IBP OE |
Associated |
3.0 |
24113176
|
acc1346 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
MDA-MB-231 |
IBP OE |
Associated |
3.0 |
24113176
|
acc1347 |
mTOR |
phosphorylation |
Ser2481 |
human |
Breast Cancer |
MDA-MB-231 |
IBP OE |
Associated |
3.0 |
24113176
|
acc1348 |
FOXO3a |
phosphorylation |
Thr32 |
human |
Breast Cancer |
MDA-MB-231 |
IBP OE |
Associated |
3.0 |
24113176
|
acc1349 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
A549 |
Resveratrol |
Associated |
4.0 |
31665911
|
acc1350 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
A549 |
Resveratrol |
Associated |
4.0 |
31665911
|